At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Insulin Aspart +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Impact of Biphasic Insulin Aspart 30 (BiAsp 30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.
In Brief
A Phase 4 clinical trial evaluating Insulin Aspart, Insulin Aspart 30, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aim of the study is to investigate meal-related treatment with either premixed Insulin Aspart 30, Aspart 70 and Aspart with regard to postprandial glucose, triglyceride and free fatty acids excursions after a standard breakfast and lunch.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesAustria
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
Primary CompletionFeb 2011
First PostedFeb 2011
Study CompletionMar 2011
TodayJul 2026
First PostedFeb 10, 2011
Enrollment StartJun 1, 2010
Primary CompletionFeb 1, 2011
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.4 years ago
Interventions
Insulin Aspartdrug
Patients received insulin aspart before breakfast and before lunch.
Insulin Aspart 30drug
Patients received biphasic insulin aspart 30 before breakfast and before lunch.
Insulin Aspart 70drug
Patients received biphasic insulin aspart 70 before breakfast and before lunch.